The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Reading Rheum

Reading Rheum

April 1, 2009 • By Eric Schned, MD; Michael M. Ward, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

This study showed that the two drugs are similar in maintaining remission after induction in the AAVs. However, perhaps surprisingly, the hypothesis that MTX would be a safer alternative was not proven. Why might this be the case? One possibility is that the target dose of MTX (25 mg per week) was higher than doses commonly used in RA and other inflammatory arthritides. In addition, significant numbers of patients had renal disease. That the presence of renal disease may have influenced the frequency of ADEs is suggested by findings in the NORAN trial (Nonrenal Wegener’s Granulomatosis Treated Alternatively with Methotrexate) in which ADEs led to discontinuation of the drug in only 8% of patients.5 In the present study, there was no association between the frequency and severity of ADEs and renal impairment in the MTX group, but numbers were relatively small.

You Might Also Like
  • Reading Rheum
  • Reading Rheum
  • Reading Rheum
Explore This Issue
April 2009

I see both good and bad news in the outcome of this study. Both AZA and MTX are effective as maintenance medications in patients with AAV achieving remission, so the clinician has options and might tailor maintenance therapy to the individual. However, both agents have a significant failure rate as measured by late relapses and significant ADEs. Clearly, more refined treatment regimens—both induction and maintenance—are required. Based on extensive experience using MTX relatively safely for RA and other arthritic diseases, I think that many clinicians, including myself, may still consider MTX the preferred agent for maintenance in individuals with more limited forms of AAV—for example, in patients with no renal disease or other high-risk disease features and for whom lower doses of MTX might be adequate.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Haubitz M, Schellong S, Gobel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement. Arthritis Rheum. 1998;41:1835-1844.
  2. Guillerin L, Cordier JF, Lhote F, et al. A prospective, multi-center, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of Wegener’s granulomatosis. Arthritis Rheum. 1997;40:2187-2198.
  3. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutophil cytoplasmic antibodies. N Engl J Med. 2003; 349:36-44.
  4. Langford C, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener’s granulomatosis: extended follow-up and rate of relapse. Am J Med. 2003;114:463-469.
  5. deGroot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005; 52:2461-2469.

 

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Research Reviews Tagged With: Pain Medication, Reading Rheum, VasculitisIssue: April 2009

You Might Also Like:
  • Reading Rheum
  • Reading Rheum
  • Reading Rheum
  • Reading Rheum

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)